Peptide Directory

A melanocortin agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, supported by large randomized controlled trials.

A stabilized GHRH analog approved for HIV-associated lipodystrophy, with visceral-fat reduction demonstrated in phase 3 trials.

A dual-incretin agonist targeting both GIP and GLP-1 receptors, with weight-reduction results exceeding single-agonist therapies in head-to-head trials.

A copper-binding tripeptide found in human plasma, extensively studied in skin-repair and cosmetic contexts.

An investigational triple-agonist in late-stage trials, with phase 2 data showing the largest weight reductions yet reported for an incretin therapy.

A 15-amino-acid fragment derived from a protective protein in gastric juice, studied primarily in animal models of tendon, ligament, muscle, and gastrointestinal injury.

A GHRH analog engineered for extended half-life, studied for its ability to raise growth hormone and IGF-1 levels.

A selective growth-hormone secretagogue studied for GH release with minimal effect on cortisol and prolactin.

A mitochondrial-encoded peptide studied in metabolism and exercise-physiology research.

A synthetic version of a naturally occurring actin-binding peptide studied in models of tissue repair, cell migration, and cardiac injury.

A growth-hormone fragment studied for fat metabolism; failed to meet endpoints in obesity trials.

A tetrapeptide studied primarily in Russian longevity research; Western replication remains minimal.

An anxiolytic heptapeptide approved in Russia as a nasal spray; minimal Western clinical data.

A nootropic-classified heptapeptide used clinically in Russia for stroke and cognitive indications.